CPD · Women 50+
Meridian
Language
Track
OverviewCurriculumEvidence graderLibraryMy progress
Overall completion0%
Modules · Primary care
01Reproductive Aging and the STRAW+10 Map02Vasomotor Symptoms: KNDy Neurons and the Thermoneutral Zone03Menopausal Hormone Therapy: Reading WHI Properly04Prescribing MHT: Routes, Regimens and Progestogen Choice05Non-Hormonal Therapy for Vasomotor Symptoms06Genitourinary Syndrome of Menopause07Bone Loss, Fracture Risk and the Sarcopenia Overlap08Cardiometabolic Change After 5009Brain Fog, Mood and Sleep10The Menopause Consultation: Equity, Risk Communication and Review

Educational content for registered health professionals. Not a substitute for current national guidance, product licences or clinical judgement.

Back to module
Evidence summary

Brain Fog, Mood and Sleep

Meridian · Women's Health After 50Generated: 4 August 2026

09Brain Fog, Mood and Sleep

Real, measurable, mostly transient — and frequently misdiagnosed as depression or early dementia.

Key takeaways

  • —SWAN's cognitive substudy demonstrated a measurable but small decline in processing speed and verbal memory during the transition, with recovery in postmenopause.
  • —The transition is a window of vulnerability for new and recurrent depression, especially with a prior history or PMDD.
  • —Sleep disruption is often multifactorial: VMS awakenings, primary insomnia, restless legs and undiagnosed OSA, which rises sharply after menopause.
  • —Oestrogen has evidence for depressive symptoms in the perimenopause but not in established postmenopausal major depression.
  • —WHIMS: MHT initiated after 65 increased dementia incidence — prevention is not an indication at any age.

Graded claims

B

Cognitive performance dips during the transition and recovers postmenopause

Supported in defined populationsSWAN cognitive substudy, longitudinal within-woman design.

B

The perimenopause is a window of increased depression risk

Supported in defined populationsHarvard Study of Moods and Cycles, SWAN, Penn Ovarian Aging Study.

B

Transdermal estradiol reduces depressive symptoms in perimenopausal women

Supported in defined populationsMultiple small RCTs including Gordon 2018 prevention trial.

B

MHT started after age 65 increases dementia risk

Supported in defined populationsWHIMS — combined arm; oestrogen-alone arm directionally similar but non-significant.

F

MHT prevents Alzheimer's disease

Refuted or actively misleadingNo supporting RCT evidence; not an indication.

B

Obstructive sleep apnoea prevalence increases after menopause

Supported in defined populationsConsistent cohort data; often missed because presentation differs from men.

Supporting references

  1. Longitudinal changes in cognition in the menopausal transition (SWAN) — Greendale et al., Neurology 2009 https://pubmed.ncbi.nlm.nih.gov/19487648/
  2. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms — Gordon et al., JAMA Psychiatry 2018 https://pubmed.ncbi.nlm.nih.gov/29322164/
  3. Conjugated Equine Estrogens and Incidence of Probable Dementia (WHIMS) — Shumaker et al., JAMA 2003 https://pubmed.ncbi.nlm.nih.gov/12771112/
Educational summary for registered health professionals. Grades reflect strength of evidence at the time of writing and do not replace current national guidance, product licences or clinical judgement.